AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21176627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 164
Study 21176627 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PCI (PCI within 24 h)
Number of subjects: 164
Study 21176627 — intervention group
Group type: COMPARATOR
Intervention: Delayed PCI (PCI after 36 h)
Number of subjects: 164
Study 21176627 — intervention group
Group type: COMPARATOR
Intervention: No cilostazol
Number of subjects: 164
Study 18935732 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 30
Study 18935732 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine followed by normal saline (control)
Number of subjects: 30
Study 15811981 — intervention group
Group type: EXPERIMENTAL
Intervention: 380 mg long-acting naltrexone
Number of subjects: 624
Study 15811981 — intervention group
Group type: EXPERIMENTAL
Intervention: 190 mg long-acting naltrexone
Number of subjects: 624
Study 15811981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 12535744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 45
Study 12535744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 45
Study 12535744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10382134 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires
Number of subjects: 22
Study 10382134 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 22
Study 9185440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcon/HMS
Number of subjects: 32
Study 9185440 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 8447208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms kg‐1 intravenous bolus) with neurolept analgesia
Number of subjects: 56
Study 8447208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms kg‐1 intravenous bolus) with halothane
Number of subjects: 56
Study 8447208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms kg‐1 intravenous bolus) with enflurane
Number of subjects: 56
Study 8447208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms kg‐1 intravenous bolus) with isoflurane
Number of subjects: 56
Study 3961308 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of social, medical and psychological interventions
Number of subjects: 0
Study 3961308 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30312754 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (10 sessions)
Number of subjects: 31
Study 30312754 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 31
Study 30312754 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (Phase II)
Number of subjects: 31
Study 30312754 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (Phase II)
Number of subjects: 31
Study 29167975 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad™ application
Number of subjects: 60
Study 29167975 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal counseling (SVC)
Number of subjects: 60
Study 27445550 — intervention group
Group type: EXPERIMENTAL
Intervention: IPPB therapy
Number of subjects: 0
Study 27445550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IPPB and PEEP therapy
Number of subjects: 0
Study 27445550 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP therapy
Number of subjects: 0
Study 27445550 — intervention group
Group type: EXPERIMENTAL
Intervention: IPPB and PEEP therapy
Number of subjects: 0
Study 24636695 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic acupoint (Sanyinjiao, SP6)
Number of subjects: 501
Study 24636695 — intervention group
Group type: COMPARATOR
Intervention: Unrelated acupoint (Xuanzhong, GB39)
Number of subjects: 501
Study 24636695 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint
Number of subjects: 501
Study 22510537 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral physical therapy interventions
Number of subjects: 108
Study 22510537 — intervention group
Group type: COMPARATOR
Intervention: Classification-based physical therapy
Number of subjects: 108
Study 19092235 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg daily) + IPL therapy
Number of subjects: 70
Study 19092235 — intervention group
Group type: COMPARATOR
Intervention: IPL therapy alone
Number of subjects: 70
Study 17251674 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway responsiveness to methacholine in CSA patients
Number of subjects: 42
Study 17251674 — intervention group
Group type: COMPARATOR
Intervention: Airway responsiveness to methacholine in CP patients
Number of subjects: 42
Study 17251674 — intervention group
Group type: COMPARATOR
Intervention: Airway responsiveness to methacholine in control subjects
Number of subjects: 42
Study 17251674 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean of log minimum dose (Dmin) in CSA patients
Number of subjects: 42
Study 17251674 — intervention group
Group type: COMPARATOR
Intervention: Geometric mean of log minimum dose (Dmin) in CP patients
Number of subjects: 42
Study 17251674 — intervention group
Group type: COMPARATOR
Intervention: Geometric mean of log minimum dose (Dmin) in control subjects
Number of subjects: 42
Study 15570276 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression plus superficial venous surgery
Number of subjects: 261
Study 15570276 — intervention group
Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 261
Study 12652992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0
Study 12652992 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 7968646 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) TTS 0.05 mg/day for 6 months and 0.025 mg/day for the following six months
Number of subjects: 24
Study 7968646 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) TTS 0.10 mg/day for the first 6 months and 0.05 mg/day for the following 6 months
Number of subjects: 24
Study 3112729 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (15 micrograms polysaccharide and 51 micrograms protein)
Number of subjects: 50
Study 3112729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 28851238 — intervention group
Group type: EXPERIMENTAL
Intervention: Templestay program (Intensive Meditation)
Number of subjects: 51
Study 28851238 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (Control)
Number of subjects: 51
Study 28061319 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent and parent motivational intervention (Arm 1)
Number of subjects: 67
Study 28061319 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent control and parent motivational intervention (Arm 2)
Number of subjects: 67
Study 28061319 — intervention group
Group type: COMPARATOR
Intervention: Adolescent and parent control (Arm 3)
Number of subjects: 67
Study 26319483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (1.0 mg/kg)
Number of subjects: 4494
Study 26319483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4494
Study 23354394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter orange extract (approximately 49mg p-synephrine) plus naringin and hesperidin, twice daily for 60 days
Number of subjects: 25
Study 23354394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter orange extract (approximately 49mg p-synephrine) alone, twice daily for 60 days
Number of subjects: 25
Study 23354394 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 60 days
Number of subjects: 25
Study 20847735 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in obesity prevention trial
Number of subjects: 804
Study 20847735 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with college education
Number of subjects: 804
Study 20847735 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with overweight vs. obese
Number of subjects: 804
Study 18691700 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure session with safety gear (gloves and goggles)
Number of subjects: 62
Study 18691700 — intervention group
Group type: COMPARATOR
Intervention: Exposure session without safety gear (control group)
Number of subjects: 62
Study 16831092 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg JS2 DNA
Number of subjects: 30
Study 16831092 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg JS2 DNA
Number of subjects: 30
Study 16831092 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 16831092 — intervention group
Group type: EXPERIMENTAL
Intervention: JS2 DNA (both doses)
Number of subjects: 30
Study 12723015 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Atenolol
Number of subjects: 28
Study 12723015 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Prazosin
Number of subjects: 28
Study 12723015 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 28
Study 10770766 — intervention group
Group type: COMPARATOR
Intervention: Quinine at 10 mg/kg three times a day for 7 days (Q)
Number of subjects: 268
Study 10770766 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin at 20 mg/kg followed by quinine for 3 days (AQ3)
Number of subjects: 268
Study 10770766 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin at 20 mg/kg followed by quinine for 5 days (AQ5)
Number of subjects: 268
Study 10770766 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 268
Study 10770766 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 268
Study 9340504 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bolus alteplase (50 mg over 1-3 minutes followed by 50 mg 30 minutes later, or 40 mg for patients <60 kg)
Number of subjects: 7169
Study 9340504 — intervention group
Group type: COMPARATOR
Intervention: Accelerated infusion of alteplase (100 mg over 90 minutes)
Number of subjects: 7169
Study 9340504 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bolus alteplase
Number of subjects: 7169
Study 9340504 — intervention group
Group type: COMPARATOR
Intervention: Accelerated infusion of alteplase
Number of subjects: 7169
Study 8438914 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diathermy excision
Number of subjects: 300
Study 8438914 — intervention group
Group type: COMPARATOR
Intervention: Laser excisional conization
Number of subjects: 300
Study 3110981 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 400 micrograms, twice daily for up to 8 weeks
Number of subjects: 60
Study 3110981 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg, twice daily for up to 8 weeks
Number of subjects: 60
Study 3110981 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 60
Study 3110981 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 60
Study 31517517 — intervention group
Group type: EXPERIMENTAL
Intervention: Societal cost information provided to patients
Number of subjects: 184
Study 31517517 — intervention group
Group type: COMPARATOR
Intervention: No societal cost information provided to patients
Number of subjects: 184
Study 31517517 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients declining surgery
Number of subjects: 184
Study 29856928 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE; alternating 100% and 50% of peak oxygen uptake)
Number of subjects: 15
Study 29856928 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Exercise (CME; 60% of peak oxygen uptake)
Number of subjects: 15
Study 28837213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 20
Study 28837213 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 20
Study 26963198 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pedicled buccal fat pad graft (BFPG)
Number of subjects: 12
Study 26963198 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 12
Study 23123438 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation that induces visible muscle contraction (MOTOR group)
Number of subjects: 76
Study 23123438 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with an intensity just above the sensory threshold (SENSORY group)
Number of subjects: 76
Study 20397896 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) fluorescence-guided microsurgery
Number of subjects: 349
Study 20397896 — intervention group
Group type: COMPARATOR
Intervention: Conventional white light (WL) microsurgery
Number of subjects: 349
Study 20397896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint of risks and neurological deficits in ALA group
Number of subjects: 349
Study 20397896 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete resections in ALA group
Number of subjects: 349
Study 20397896 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Scale (KPS) score
Number of subjects: 349
Study 19213086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg
Number of subjects: 3528
Study 19213086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.75 mg/kg
Number of subjects: 3528
Study 19213086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg with closure device
Number of subjects: 3528
Study 19213086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.75 mg/kg with closure device
Number of subjects: 3528
Study 19213086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg with smaller sheath size (<7 Fr)
Number of subjects: 3528
Study 19213086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.75 mg/kg with smaller sheath size (<7 Fr)
Number of subjects: 3528
Study 19213086 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3528
Study 17853749 — intervention group
Group type: EXPERIMENTAL
Intervention: EA at Qiuxu (GB 40)
Number of subjects: 275
Study 17853749 — intervention group
Group type: COMPARATOR
Intervention: EA at Tianshu (ST 25)
Number of subjects: 275
Study 15111165 — intervention group
Group type: EXPERIMENTAL
Intervention: PMEA-coated circuit (group P)
Number of subjects: 45
Study 15111165 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (group H)
Number of subjects: 45
Study 15111165 — intervention group
Group type: COMPARATOR
Intervention: Noncoated circuit (group N)
Number of subjects: 45
Study 11266495 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation training
Number of subjects: 32
Study 11266495 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical care only)
Number of subjects: 32
Study 9153333 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrotal system (Testoderm Testosterone Transdermal System) delivering approximately 4 mg testosterone over 24 hours
Number of subjects: 60
Study 9153333 — intervention group
Group type: COMPARATOR
Intervention: Nonscrotal system (Androderm Testosterone Transdermal System) providing approximately 5 mg testosterone over 24 hours
Number of subjects: 60
Study 8239592 — intervention group
Group type: EXPERIMENTAL
Intervention: SCE-2787
Number of subjects: 12
Study 8239592 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 12
Study 3687521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-fading smoking program
Number of subjects: 0
Study 3687521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerstrom Tolerance Questionnaire (FTQ)
Number of subjects: 0
Study 28481837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 129
Study 28481837 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 129
Study 26398327 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise self‐monitoring plus incentives ($2 per day for diary submissions)
Number of subjects: 27
Study 26398327 — intervention group
Group type: COMPARATOR
Intervention: Home‐based exercise self‐monitoring program (control)
Number of subjects: 27
Study 25631635 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth program (3 video conferencing interviews + 1 hospital visit for low-risk; 6 hospital visits + 6 video conferencing for high-risk)
Number of subjects: 250
Study 25631635 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (4 hospital visits per year for low-risk; 6 hospital visits for high-risk)
Number of subjects: 250
Study 24014884 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil continuous infusion (800 mg/m2/day, ci, d1-5, q4w)
Number of subjects: 237
Study 24014884 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and 5-fluorouracil therapy (methotrexate, 100 mg/m2, bolus infusion, followed 3 h later by 5-fluorouracil, 600 mg/m2, bolus infusion, with leucovorin rescue, q1w)
Number of subjects: 237
Study 21911948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% (Colgate Periogard)
Number of subjects: 18
Study 21911948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride 0.05% (Johnson and Johnson's Reach)
Number of subjects: 18
Study 21911948 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 18
Study 18454257 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural honey (70 g daily for 30 days)
Number of subjects: 55
Study 18454257 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (70 g daily for 30 days)
Number of subjects: 55
Study 16911289 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT) (160 mg g1)
Number of subjects: 30
Study 16911289 — intervention group
Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 30
Study 16911289 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT)
Number of subjects: 30
Study 12821233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetylcysteine (NAC) 150 mg/kg in 500 ml N/saline over 30 min immediately before contrast followed by 50 mg/kg in 500 ml N/saline over 4 h (n = 41)
Number of subjects: 80
Study 12821233 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration (1 ml/kg/h N/saline for 12 h pre‐ and post‐contrast, n = 39)
Number of subjects: 80
Study 10913474 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab plus heparin (70 U/kg)
Number of subjects: 46
Study 10913474 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (70 U/kg)
Number of subjects: 46
Study 8902660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 8
Study 8902660 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 1517792 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 16 mg/kg and Cyclophosphamide (CY) 120 mg/kg
Number of subjects: 20
Study 1517792 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 120 mg/kg
Number of subjects: 20
Study 1517792 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 147 mg/kg
Number of subjects: 20
Study 1517792 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 174 mg/kg
Number of subjects: 20
Study 1517792 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 20
Study 6471030 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine A
Number of subjects: 0
Study 6471030 — intervention group
Group type: COMPARATOR
Intervention: Influenza Vaccine B
Number of subjects: 0
Study 6471030 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up study
Number of subjects: 0
Study 28658080 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGHW:R‐3×15:44s
Number of subjects: 20
Study 28658080 — intervention group
Group type: EXPERIMENTAL
Intervention: LOWW:R‐3×15:88s
Number of subjects: 20
Study 28658080 — intervention group
Group type: EXPERIMENTAL
Intervention: LOWW:R‐45×1:4s
Number of subjects: 20
Study 28658080 — intervention group
Group type: EXPERIMENTAL
Intervention: LOWW:R‐9×5:22s
Number of subjects: 20
Study 29843654 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (50-min presentation by a skin cancer specialist nurse and young adult skin cancer survivor)
Number of subjects: 639
Study 29843654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 639
Study 26641555 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance improvement interventions including physician education, case management, web-based decision support (CareManager(TM)), and performance feedback.
Number of subjects: 242
Study 26641555 — intervention group
Group type: EXPERIMENTAL
Intervention: CareManager(TM) implementation and health system-wide COPD performance improvement efforts.
Number of subjects: 242
Study 26641555 — intervention group
Group type: EXPERIMENTAL
Intervention: CareManager(TM) and performance improvement interventions.
Number of subjects: 242
Study 26641555 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for patients naïve to depression screening, pneumococcal vaccination, inhaled control medications, or smoking cessation.
Number of subjects: 242
Study 25031533 — intervention group
Group type: EXPERIMENTAL
Intervention: AKL1
Number of subjects: 33
Study 25031533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23300553 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulating anger via reappraisal
Number of subjects: 0
Study 23300553 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulating anger via distraction
Number of subjects: 0
Study 23300553 — intervention group
Group type: COMPARATOR
Intervention: Angered participants
Number of subjects: 0
Study 20716817 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 vaccine (3x10^9, 3x10^10, and 3x10^11 DNase resistant particles/ml)
Number of subjects: 30
Study 20716817 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 vaccine (high dose)
Number of subjects: 30